According to a recent LinkedIn post from Laplace Interventional, the company’s Laplace TTVR device was featured in a JACC: Case Reports article detailing treatment of torrential tricuspid regurgitation in a patient with complex anatomy. The post notes that a previously planned commercial tricuspid procedure was aborted due to insufficient right atrial height, while Laplace TTVR reportedly enabled a successful intervention.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights that, following use of Laplace TTVR, tricuspid regurgitation was described as completely eliminated and the patient’s functional status and quality of life were reported to have improved. For investors, this publication-based case exposure may suggest early clinical validation in anatomically challenging patients, which could support future adoption, reimbursement discussions and competitive positioning in the transcatheter tricuspid valve replacement segment.